This site is intended for health professionals only
Friday 13 July 2018
Share |

Sandoz's biosimilar etanercept has equivalent efficacy to originator product

Related articles

Cimzia can be used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, following label extension by European Medicines Agency (EMA)

Sandoz has announced results from the EGALITY trial in which the primary endpoint of achieving equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 was met.

The study compared the safety and efficacy of its biosimilar etanercept candidate with the originator product, Enbrel® in patients with moderate-to-severe chronic plaque-type psoriasis and was presented at Psoriasis 2016, the 5th Congress of the Psoriasis International Network (PIN), Paris, France.

Ads by Google